280 related articles for article (PubMed ID: 25890768)
1. Nanoparticle formulation of ormeloxifene for pancreatic cancer.
Khan S; Chauhan N; Yallapu MM; Ebeling MC; Balakrishna S; Ellis RT; Thompson PA; Balabathula P; Behrman SW; Zafar N; Singh MM; Halaweish FT; Jaggi M; Chauhan SC
Biomaterials; 2015; 53():731-43. PubMed ID: 25890768
[TBL] [Abstract][Full Text] [Related]
2. Ormeloxifene nanotherapy for cervical cancer treatment.
Chauhan N; Maher DM; Hafeez BB; Mandil H; Singh MM; Yallapu MM; Jaggi M; Chauhan SC
Int J Nanomedicine; 2019; 14():7107-7121. PubMed ID: 31564868
[TBL] [Abstract][Full Text] [Related]
3. Mithramycin-loaded mPEG-PLGA nanoparticles exert potent antitumor efficacy against pancreatic carcinoma.
Liu XJ; Li L; Liu XJ; Li Y; Zhao CY; Wang RQ; Zhen YS
Int J Nanomedicine; 2017; 12():5255-5269. PubMed ID: 28769562
[TBL] [Abstract][Full Text] [Related]
4. Novel curcumin-loaded magnetic nanoparticles for pancreatic cancer treatment.
Yallapu MM; Ebeling MC; Khan S; Sundram V; Chauhan N; Gupta BK; Puumala SE; Jaggi M; Chauhan SC
Mol Cancer Ther; 2013 Aug; 12(8):1471-80. PubMed ID: 23704793
[TBL] [Abstract][Full Text] [Related]
5. Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells.
Yallapu MM; Gupta BK; Jaggi M; Chauhan SC
J Colloid Interface Sci; 2010 Nov; 351(1):19-29. PubMed ID: 20627257
[TBL] [Abstract][Full Text] [Related]
6. Salinomycin nanoparticles interfere with tumor cell growth and the tumor microenvironment in an orthotopic model of pancreatic cancer.
Daman Z; Faghihi H; Montazeri H
Drug Dev Ind Pharm; 2018 Sep; 44(9):1434-1442. PubMed ID: 29619850
[TBL] [Abstract][Full Text] [Related]
7. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel.
Feng SS; Mei L; Anitha P; Gan CW; Zhou W
Biomaterials; 2009 Jul; 30(19):3297-306. PubMed ID: 19299012
[TBL] [Abstract][Full Text] [Related]
8. PLGA/poloxamer nanoparticles loaded with EPAS1 siRNA for the treatment of pancreatic cancer in vitro and in vivo.
Pan X; Zhu Q; Sun Y; Li L; Zhu Y; Zhao Z; Zuo J; Fang W; Li K
Int J Mol Med; 2015 Apr; 35(4):995-1002. PubMed ID: 25672594
[TBL] [Abstract][Full Text] [Related]
9. Development of poly(lactic-co-glycolic) acid nanoparticles-embedded hyaluronic acid-ceramide-based nanostructure for tumor-targeted drug delivery.
Park JH; Lee JY; Termsarasab U; Yoon IS; Ko SH; Shim JS; Cho HJ; Kim DD
Int J Pharm; 2014 Oct; 473(1-2):426-33. PubMed ID: 25079433
[TBL] [Abstract][Full Text] [Related]
10. Facile one-pot formulation of TRAIL-embedded paclitaxel-bound albumin nanoparticles for the treatment of pancreatic cancer.
Min SY; Byeon HJ; Lee C; Seo J; Lee ES; Shin BS; Choi HG; Lee KC; Youn YS
Int J Pharm; 2015 Oct; 494(1):506-15. PubMed ID: 26315118
[TBL] [Abstract][Full Text] [Related]
11. Transferrin surface-modified PLGA nanoparticles-mediated delivery of a proteasome inhibitor to human pancreatic cancer cells.
Frasco MF; Almeida GM; Santos-Silva F; Pereira Mdo C; Coelho MA
J Biomed Mater Res A; 2015 Apr; 103(4):1476-84. PubMed ID: 25046528
[TBL] [Abstract][Full Text] [Related]
12. Translocator protein ligand-PLGA conjugated nanoparticles for 5-fluorouracil delivery to glioma cancer cells.
Laquintana V; Denora N; Lopalco A; Lopedota A; Cutrignelli A; Lasorsa FM; Agostino G; Franco M
Mol Pharm; 2014 Mar; 11(3):859-71. PubMed ID: 24410438
[TBL] [Abstract][Full Text] [Related]
13. Surface modification of PLGA nanoparticles with biotinylated chitosan for the sustained in vitro release and the enhanced cytotoxicity of epirubicin.
Chen H; Xie LQ; Qin J; Jia Y; Cai X; Nan W; Yang W; Lv F; Zhang QQ
Colloids Surf B Biointerfaces; 2016 Feb; 138():1-9. PubMed ID: 26638176
[TBL] [Abstract][Full Text] [Related]
14. Poly aspartic acid peptide-linked PLGA based nanoscale particles: potential for bone-targeting drug delivery applications.
Jiang T; Yu X; Carbone EJ; Nelson C; Kan HM; Lo KW
Int J Pharm; 2014 Nov; 475(1-2):547-57. PubMed ID: 25194353
[TBL] [Abstract][Full Text] [Related]
15. Ifosfamide-loaded poly (lactic-co-glycolic acid) PLGA-dextran polymeric nanoparticles to improve the antitumor efficacy in Osteosarcoma.
Chen B; Yang JZ; Wang LF; Zhang YJ; Lin XJ
BMC Cancer; 2015 Oct; 15():752. PubMed ID: 26486165
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic designed poly (lactic-co-glycolic acid) cylindrical oseltamivir phosphate-loaded implants impede tumor neovascularization, growth and metastasis in mouse model of human pancreatic carcinoma.
Hrynyk M; Ellis JP; Haxho F; Allison S; Steele JA; Abdulkhalek S; Neufeld RJ; Szewczuk MR
Drug Des Devel Ther; 2015; 9():4573-86. PubMed ID: 26309402
[TBL] [Abstract][Full Text] [Related]
17. Low-molecular-weight protamine-modified PLGA nanoparticles for overcoming drug-resistant breast cancer.
Wang H; Zhao Y; Wang H; Gong J; He H; Shin MC; Yang VC; Huang Y
J Control Release; 2014 Oct; 192():47-56. PubMed ID: 25003794
[TBL] [Abstract][Full Text] [Related]
18. Development of innovative paclitaxel-loaded small PLGA nanoparticles: study of their antiproliferative activity and their molecular interactions on prostatic cancer cells.
Le Broc-Ryckewaert D; Carpentier R; Lipka E; Daher S; Vaccher C; Betbeder D; Furman C
Int J Pharm; 2013 Oct; 454(2):712-9. PubMed ID: 23707251
[TBL] [Abstract][Full Text] [Related]
19. Development and characterization of folate anchored Saquinavir entrapped PLGA nanoparticles for anti-tumor activity.
Singh R; Kesharwani P; Mehra NK; Singh S; Banerjee S; Jain NK
Drug Dev Ind Pharm; 2015; 41(11):1888-901. PubMed ID: 25738812
[TBL] [Abstract][Full Text] [Related]
20. Development of a poly(d,l-lactic-co-glycolic acid) nanoparticle formulation of STAT3 inhibitor JSI-124: implication for cancer immunotherapy.
Molavi O; Mahmud A; Hamdy S; Hung RW; Lai R; Samuel J; Lavasanifar A
Mol Pharm; 2010 Apr; 7(2):364-74. PubMed ID: 20030320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
